Former Pfizer executives to lead regulatory affairs group based in Ann
BETHESDA, Md., Feb. 25 /PRNewswire/ -- United BioSource Corporation (UBC) today announced the expansion of its Regulatory Affairs group led by distinguished experts Mark Ammann, Pharm.D. and LaVonne Lang, Dr PH. Based in Ann Arbor, Michigan, the group will provide a full range of services to pharmaceutical and biotechnology clients, including creating and implementing development plans to fulfill regulatory requirements for initial approval of new medicines and providing life-cycle management for marketed products.
The Regulatory Affairs group will be headed by Dr. Mark Ammann, a 17-year veteran of the pharmaceutical industry, who has worked with products from early development to post-marketing product support in such diverse therapeutic areas as CNS, oncology, dermatology, inflammation, endocrinology and cardiovascular disorders. Dr. Ammann most recently held the position of Global Head of Regulatory Affairs at Pfizer Corporation where he was responsible for several therapeutic areas including central nervous system, inflammation and dermatology.
"We are thrilled to welcome Dr. Ammann and Dr. Lang to the UBC team. They give us world-class experience and expertise in navigating through the drug development process with the FDA. This capability complements our specialized regulatory knowledge in areas like health outcomes and post-approval research to provide clients unique regulatory insight in both the pre- and post- approval environment," according to Ethan Leder, UBC CEO and Founder.
"Having led many interactions with the FDA over the past 16 years, I am
particularly excited about helping clients navigate through the maze of
evolving regulations, offering the
|SOURCE United BioSource Corporation|
Copyright©2008 PR Newswire.
All rights reserved